Insider · CIK 0001945797
Kevin Lee Freeman
Files at HCAT (Health Catalyst, Inc.). First filing Dec 3, 2024, latest Dec 3, 2024.
In brief
Kevin Lee Freeman files SEC Form 4 as officer at HCAT (Health Catalyst, Inc.). Since Dec 3, 2024, Kevin Lee Freeman has reported 0 open-market buys worth $0 and 1 open-market sell worth $67k, the latest filed on Dec 3, 2024.
A track record needs three past buys with six months of prices behind them; Kevin Lee Freeman has 0, so none is measured yet.
The newest scored trade: sold $67k of HCAT on Dec 2, 2024, filed Dec 3, 2024, scored 18 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HCAT: Health Catalyst, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Health Catalyst, Inc. | $67k 7,500 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 2, 2026 | HCAT Health Catalyst, Inc. | 15,726 0.02% of outstanding | $26k | Mar 2, 2026 | $59k |
| Feb 26, 2026 | HCAT Health Catalyst, Inc. | 6,614 0.01% of outstanding | $12k | Feb 26, 2026 | $48k |
| Dec 1, 2025 | HCAT Health Catalyst, Inc. | 16,401 0.02% of outstanding | $48k | Dec 1, 2025 | $15k |
| Sep 2, 2025 | HCAT Health Catalyst, Inc. | 4,578 0.01% of outstanding | $15k | Sep 2, 2025 | $17k |
| Jun 2, 2025 | HCAT Health Catalyst, Inc. | 4,747 0.01% of outstanding | $17k | Jun 2, 2025 | $49k |
| Mar 3, 2025 | HCAT Health Catalyst, Inc. | 10,800 0.02% of outstanding | $49k | Mar 3, 2025 | $170k |
| Dec 2, 2024 | HCAT Health Catalyst, Inc. | 11,431 0.02% of outstanding | $103k | Dec 2, 2024 | $74k |
| Dec 2, 2024 | HCAT HEALTH CATALYST INC | 7,500 0.01% of outstanding | $66k | Dec 2, 2024 | $54k |
| Dec 1, 2023 | HCAT Health Catalyst, Inc. | 2,921 0.01% of outstanding | $22k | Dec 1, 2023 | $100k |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | HCAT Health Catalyst, Inc. | FTax withholding Common Stock | -16,401 | $2.90 | $48k | 358,686 | Dec 3, 2025 |
| Sep 2, 2025 | HCAT Health Catalyst, Inc. | FTax withholding Common Stock | -4,578 | $3.36 | $15k | 375,087 | Sep 4, 2025 |
| Jun 2, 2025 | HCAT Health Catalyst, Inc. | FTax withholding Common Stock | -4,747 | $3.63 | $17k | 379,665 | Jun 3, 2025 |
| Mar 3, 2025 | HCAT Health Catalyst, Inc. | FTax withholding Common Stock | -10,800 | $4.58 | $49k | 384,412 | Mar 4, 2025 |
| Feb 20, 2025 | HCAT Health Catalyst, Inc. | AGrant or award Common Stock | +140,000 | $0.00 | $0 | 376,950 | Feb 24, 2025 |
| Feb 20, 2025 | HCAT Health Catalyst, Inc. | AGrant or award Common Stock | +18,262 | $0.00 | $0 | 395,212 | Feb 24, 2025 |
| Dec 1, 2024 | HCAT Health Catalyst, Inc. | FTax withholding Common Stock | -11,431 | $8.97 | $103k | 244,450 | Dec 3, 2024 |
| Dec 2, 2024 | HCAT Health Catalyst, Inc. | SOpen-market sale Common Stock10b5-1 | -7,500 | $8.94 | $67k | 236,950 | Dec 3, 2024 |
Questions about Kevin Lee Freeman
Answered from the filings on this page, as of the latest one.
Is Kevin Lee Freeman buying or selling?
Not in the last 12 months. Kevin Lee Freeman's latest open-market trade on SEC Form 4 was sold $67k of HCAT on Dec 2, 2024.
How did Kevin Lee Freeman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin Lee Freeman has 0.
Where does Kevin Lee Freeman file Form 4?
Kevin Lee Freeman has filed Form 4 at HCAT (Health Catalyst, Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.